|
gptkbp:instanceOf
|
gptkb:vaccine
|
|
gptkbp:adjuvant
|
aluminum hydroxide
|
|
gptkbp:administeredBy
|
adults
children (in some countries)
|
|
gptkbp:antigen
|
inactivated SARS-CoV-2 virus
|
|
gptkbp:approvedBy
|
2020
|
|
gptkbp:boosterDoseAvailable
|
yes
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:countryOfOrigin
|
gptkb:China
|
|
gptkbp:developedBy
|
gptkb:Sinovac_Biotech
|
|
gptkbp:dosesRequired
|
2
|
|
gptkbp:efficacyAgainstSevereCOVID19
|
100% (Brazil trial)
|
|
gptkbp:efficacyAgainstSymptomaticCOVID19
|
51% (Brazil trial)
|
|
gptkbp:emergencyServices
|
gptkb:Brazil
gptkb:Chile
gptkb:Egypt
gptkb:Hungary
gptkb:Indonesia
gptkb:Malaysia
gptkb:Mexico
gptkb:Philippines
gptkb:Thailand
gptkb:Turkey
gptkb:World_Health_Organization
|
|
gptkbp:includedInCOVAX
|
yes
|
|
gptkbp:intervalBetweenDoses
|
2–4 weeks
|
|
gptkbp:manufacturer
|
gptkb:Sinovac_Biotech
|
|
gptkbp:regulates
|
approved in multiple countries
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
nausea
diarrhea
fatigue
headache
muscle pain
rash
pain at injection site
|
|
gptkbp:storage
|
refrigeration
2–8°C
|
|
gptkbp:suitableForLowResourceSettings
|
yes
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:type
|
inactivated virus vaccine
|
|
gptkbp:usedIn
|
over 40 countries
|
|
gptkbp:usedInMassVaccination
|
yes
|
|
gptkbp:WHOEmergencyUseListing
|
2021-06-01
|
|
gptkbp:WHOListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Sinovac_COVID-19_vaccine
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CoronaVac
|